Pharmaxis Ltd’s Gary Phillips speaks to Proactive following the news they’ve been cleared to progress its bone marrow cancer trial to a phase 2 dose expansion phase. It follows further positive
results of data analysis from the phase 1c clinical trial of its drug PXS‐5505.
source
